Éric Yvon

4.6k total citations · 2 hit papers
18 papers, 3.3k citations indexed

About

Éric Yvon is a scholar working on Immunology, Oncology and Neurology. According to data from OpenAlex, Éric Yvon has authored 18 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 7 papers in Oncology and 6 papers in Neurology. Recurrent topics in Éric Yvon's work include Immune Cell Function and Interaction (10 papers), Immunotherapy and Immune Responses (6 papers) and Neuroblastoma Research and Treatments (6 papers). Éric Yvon is often cited by papers focused on Immune Cell Function and Interaction (10 papers), Immunotherapy and Immune Responses (6 papers) and Neuroblastoma Research and Treatments (6 papers). Éric Yvon collaborates with scholars based in United States, France and Australia. Éric Yvon's co-authors include Marina Cavazzana, Fabian Gross, Salima Hacein‐Bey, Geneviève de Saint Basile, Jean‐Laurent Casanova, Alain Fischer, Françoise Le Deist, Stéphanie Certain, Patrick Nusbaum and Philippe Bousso and has published in prestigious journals such as Science, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Éric Yvon

18 papers receiving 3.1k citations

Hit Papers

Gene Therapy of Human Severe Combined Immunodeficiency (S... 2000 2026 2008 2017 2000 2008 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
    2000 1.8k citations Marina Cavazzana, Salima Hacein‐Bey et al. Science profile →
  2. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
    2008 919 citations Martin Pulé, Barbara Savoldo et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Éric Yvon United States 11 1.8k 1.7k 1.6k 995 304 18 3.3k
David DiGiusto United States 20 766 0.4× 1.2k 0.7× 1.3k 0.8× 1.0k 1.0× 312 1.0× 49 2.8k
Bambi Grilley United States 21 1.5k 0.8× 1.2k 0.7× 3.7k 2.2× 1.5k 1.5× 920 3.0× 69 4.4k
Karin Straathof United States 23 1.4k 0.8× 1.2k 0.7× 3.6k 2.2× 1.9k 1.9× 793 2.6× 38 4.6k
Carolina Berger United States 28 1.1k 0.7× 1.2k 0.7× 3.0k 1.9× 1.5k 1.5× 782 2.6× 49 3.9k
Harjeet Singh United States 29 988 0.6× 1.2k 0.7× 2.6k 1.6× 1.4k 1.4× 701 2.3× 57 3.4k
Carolina Colli Cruz United States 26 863 0.5× 810 0.5× 2.1k 1.3× 1.4k 1.4× 529 1.7× 93 3.3k
Gregory E. Plautz United States 29 1.6k 0.9× 2.4k 1.4× 1.2k 0.8× 1.6k 1.7× 109 0.4× 56 4.2k
Daniel J. Landsburg United States 23 716 0.4× 722 0.4× 2.4k 1.5× 721 0.7× 513 1.7× 136 3.3k
Simon Olivares United States 24 995 0.6× 1.1k 0.6× 2.4k 1.5× 1.1k 1.1× 686 2.3× 46 3.0k
Ute Modlich Germany 28 2.1k 1.2× 2.8k 1.6× 1.1k 0.7× 454 0.5× 138 0.5× 78 3.7k

Countries citing papers authored by Éric Yvon

Since Specialization
Citations

This map shows the geographic impact of Éric Yvon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Yvon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Yvon more than expected).

Fields of papers citing papers by Éric Yvon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éric Yvon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Yvon. The network helps show where Éric Yvon may publish in the future.

Co-authorship network of co-authors of Éric Yvon

This figure shows the co-authorship network connecting the top 25 collaborators of Éric Yvon. A scholar is included among the top collaborators of Éric Yvon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Éric Yvon. Éric Yvon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Wu, Bogang, Xiaowen Zhang, Huai-Chin Chiang, et al.. (2022). RNA polymerase II pausing factor NELF in CD8+ T cells promotes antitumor immunity. Nature Communications. 13(1). 2155–2155. 9 indexed citations
2.
Burga, Rachel A., Elizabeth D. Williams, Éric Yvon, et al.. (2018). Generating suppression-resistant natural killer cells as an enhanced immunotherapeutic for neuroblastoma. The Journal of Immunology. 200(Supplement_1). 179.6–179.6. 2 indexed citations
3.
Yvon, Éric, Rachel A. Burga, Allison B. Powell, et al.. (2017). Cord blood natural killer cells expressing a dominant negative TGF-b receptor: Implications for adoptive immunotherapy. Cytotherapy. 19(5). S48–S49. 1 indexed citations
4.
Müftüoğlu, Muharrem, Sairah Ahmed, Amanda Olson, et al.. (2016). Use of Expanded Allogeneic Third Party BK Virus Specific Cytotoxic T Cells to Target Progressive Multifocal Leukoencephalopathy. Blood. 128(22). 3365–3365. 1 indexed citations
5.
Gargett, Tessa, Cara K. Fraser, Gianpietro Dotti, Éric Yvon, & Michael P. Brown. (2014). BRAF and MEK Inhibition Variably Affect GD2-specific Chimeric Antigen Receptor (CAR) T-Cell Function In Vitro. Journal of Immunotherapy. 38(1). 12–23. 34 indexed citations
6.
7.
Fan, Yihui, Renfang Mao, Yanling Zhao, et al.. (2009). Tumor Necrosis Factor-α Induces RelA Degradation via Ubiquitination at Lysine 195 to Prevent Excessive Nuclear Factor-κB Activation. Journal of Biological Chemistry. 284(43). 29290–29297. 14 indexed citations
8.
Russell, Heidi V., Douglas Strother, Zhuyong Mei, et al.. (2008). A Phase 1/2 Study of Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 in Patients With High-risk Neuroblastoma. Journal of Immunotherapy. 31(9). 812–819. 25 indexed citations
9.
Pulé, Martin, Barbara Savoldo, Gary D. Myers, et al.. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nature Medicine. 14(11). 1264–1270. 919 indexed citations breakdown →
10.
Russell, Heidi V., Douglas Strother, Zhuyong Mei, et al.. (2007). Phase I Trial of Vaccination With Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 and Lymphotactin. Journal of Immunotherapy. 30(2). 227–233. 37 indexed citations
11.
Rousseau, Raphaël F., Valérie Combaret, Éric Yvon, et al.. (2006). [Immunotherapy of poor-prognosis neuroblastoma in children: from bench to bedside].. PubMed. 93(2). 153–61. 1 indexed citations
12.
13.
Biagi, Ettore, Éric Yvon, Gianpietro Dotti, et al.. (2003). Bystander Transfer of Functional Human CD40 Ligand from Gene-Modified Fibroblasts to B-Chronic Lymphocytic Leukemia Cells. Human Gene Therapy. 14(6). 545–559. 22 indexed citations
14.
Rousseau, Raphaël F., Ann E. Haight, Éric Yvon, et al.. (2003). Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood. 101(5). 1718–1726. 90 indexed citations
15.
Amrolia, Persis, Éric Yvon, Helen Huls, et al.. (2003). Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 102(6). 2292–2299. 128 indexed citations
16.
Hacein‐Bey, Salima, Fabian Gross, Patrick Nusbaum, et al.. (2001). Thérapie génique du déficit immunitaire combiné sévère lié à l'X (DICS-X1). Pathologie Biologie. 49(1). 57–66. 2 indexed citations
17.
Cavazzana, Marina, Salima Hacein‐Bey, Geneviève de Saint Basile, et al.. (2000). Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease. Science. 288(5466). 669–672. 1819 indexed citations breakdown →
18.
Montagna, Daniela, Éric Yvon, Valeria Calcaterra, et al.. (1999). Depletion of Alloreactive T Cells by a Specific Anti–Interleukin-2 Receptor p55 Chain Immunotoxin Does Not Impair In Vitro Antileukemia and Antiviral Activity. Blood. 93(10). 3550–3557. 98 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David DiGiusto Breakdown of academic impact, for papers by Bambi Grilley Breakdown of academic impact, for papers by Karin Straathof Breakdown of academic impact, for papers by Carolina Berger Breakdown of academic impact, for papers by Harjeet Singh Breakdown of academic impact, for papers by Carolina Colli Cruz Breakdown of academic impact, for papers by Gregory E. Plautz Breakdown of academic impact, for papers by Daniel J. Landsburg Breakdown of academic impact, for papers by Simon Olivares Breakdown of academic impact, for papers by Ute Modlich
Rankless by CCL
2026